Participant Listing

Total Page：16

File Type：pdf, Size：1020Kb

PARTICIPANT LISTING Please find below a list of current participants in the Australian Life Sciences Remuneration Review. For a complete list by super sector, sector and segment refer to Mercer WIN®. A Menarini Australia Becton Dickinson EGO Pharmaceuticals Abbott Australasia Biogen Elekta AbbVie bioMerieux Australia Eli Lilly Australia Acrux DDS Boehringer Ingelheim Esko Alcon Boston Scientific Int’l BV Ferring Pharmaceuticals Alexion Australasia Bristol Myers Squibb Australia Fresenius Kabi Australia Allergan Cardinal Health, Inc Fresenius Medical Care Australia Alphapharm CareFusion Australia Galderma Australia Amgen Cepheid GE Australia Healthcare Aspen Australia Cochlear Gedeon Richter Australia Astellas Pharma Australia Coloplast Getinge Astrazeneca Concordia Australia Gilead Sciences Australian Pharmaceutical Industries Coopervision, Inc. Australia GlaxoSmithKline Australia Baxter Healthcare CSL Grifols Australia Bayer Device Technologies Aust Hach Beckman Coulter - Diagnostics Ecolab Halyard Health Australia Beckman Coulter - Life Sciences Edwards Lifesciences Henry Schein Halas © March 2019 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.1 PARTICIPANT LISTING Herbalife Australasia Mayne Pharma International PerkinElmer Implant Direct Medical Components, Australia Permobil Australia iNova Pharmaceuticals (Australia) Medtronic Australasia Pfizer Australia Integria Healthcare Mentholatum Australasia Pierre Fabre Australia Medicaments Inverness Medical Innovations Australia Merck Sharp & Dohme Radiometer Ipsen Metagenics (Aust) ResMed Asia Pacific IQVIA Solutions Australia Molnlycke Health Care ResMed Inc (Aust) J&J Pacific MSD International ResMed Janssen Cilag - Australia Mundipharma Roche Products Johnson & Johnson Medical Australia Nobel Biocare Sandoz Juno Pharmaceuticals Novartis Pharmaceuticals Australia Sanofi KCI Medical Australia Novo Nordisk Pharmaceuticals Sartorius Australia Kerr Novotech Sartorius Stedim Australia Leica Biosystems Novozymes AU Sciex Leica Microsystems Olympus Australia Seqirus Leo Group Ormco Servier Laboratories (Aust) Liberty Medical Ortho Clinical Diagnostics - Australia Shire Australia Life Technologies Australia Otsuka Australia Pharmaceutical Siemens Healthcare Lundbeck Australia Pall Sirtex Medical © March 2019 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.2 PARTICIPANT LISTING Specsavers & Associated Entities Straumann Australia Stryker Australia Swisse Wellness Sysmex Australia Takeda Pharmaceuticals Australia Teva Pharma Australia The Fred Hollows Foundation Trojan World Courier Zimmer Biomet © March 2019 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.3.

Copy Link

Recommended publications

2018 Annual Report
2018 Annual Report Danaher 2018 Annual Report Financial Operating Highlights (dollars in millions except per share data and number of associates) 2018 2017 Sales $ 19,893.0 $ 18,329.7 Operating Profit $ 3,403.8 $ 2,990.4 Net Earnings $ 2,650.9 $ 2,469.8 Net Earnings Per Share (diluted) $ 3.74 $ 3.50 Operating Cash Flow $ 4,022.0 $ 3,477.8 Investing Cash Flow $ (2,949.4) $ (843.4) Financing Cash Flow $ (797.4) $ (3,098.5) Capital Expenditures $ (655.7) $ (619.6) Capital Disposals $ 6.3 $ 32.6 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,372.6 $ 2,890.8 Number of Associates 71,000 67,000 Total Assets $ 47,832.5 $ 46,648.6 Total Debt * $ 9,740.3 $ 10,522.1 Stockholders’ Equity $ 28,226.7 $ 26,367.8 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 37,967.0 $ 36,889.9 * Long-Term Debt ($9,688.5 for 2018 and $10,327.4 for 2017) plus Notes Payable and Current Portion of Long-Term Debt ($51.8 for 2018 and $194.7 for 2017) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. 2018 Annual Report Dear Shareholders, As I begin my 30th year at Danaher, it is humbling to reflect on what our team has achieved over that time and exciting to think about the opportunities that still lie ahead. Financially and strategically, 2018 was an outstanding year. With the Danaher Business System (DBS) as our driving force, we strengthened our footholds in attractive, fast-growing markets and enhanced our competitive positions.
[Show full text]
Envista Holdings Corp NVST
14 October 2019 Equity Research Americas | United States Envista Holdings Corp NVST Bracing for Growth; Initiate Neutral; $30 Target Price Target price (12M, US$) 30.00 [V] Life Science Tools and Diagnostics | Initiation Neutral ■ Initiate Neutral; $30 Target Price: As a leading global manufacturer of dental, NVST is Price (11 Oct 19, US$) 27.93 levered to a seemingly stabilizing underlying dental industry backdrop, where it supports 52-week price range 29.07 - 26.59 90% of practitioners’ clinical needs. We expect earnings growth to accelerate on dedicated Market cap (US$ m) 4,431.13 innovation efforts, greater penetration in high-growth markets, and efficiency initiatives as a Enterprise value (US$ m) 5,650.91 [V] = Stock Considered Volatile (see Disclosure Appendix) more nimble standalone entity, as the recent spinoff of Danaher’s Dental segment. All in, these drivers should accelerate organic revenue growth to +low to mid-single digits over the next five years, with earnings growing at a +7% CAGR from 2019E-2023E. Research Analysts ■ Positioning for Growth via Targeted Innovation: While dental demand trends have Erin Wilson Wright been lackluster over the past few years, we view rising dental utilization stemming from 212 538 4080 favorable demographics, an emphasis on aesthetic and preventative care, along with [email protected] expanding adoption of digital dentistry should drive improving demand for dental Katie Tryhane consumables and equipment long term. For NVST, reinvigorated innovation, focused on 212 325 2713 Specialty products (i.e. N1 Implants, Spark Clear Aligners), an inherently faster growing [email protected] category (48% of sales), should spur growth, alongside efforts to fortify Dental Support Org.
[Show full text]
Participant List
Participant list Please find below a list of current participants in theAustralian Life Sciences Remuneration Review. For a complete list by super sector, sector and segment refer to Mercer WIN®. A Menarini Australia Beckman Coulter – Diagnostics Ego Pharmaceuticals AbbVie Australia Beckman Coulter – Life Sciences Elanco Australasia Alcon Becton Dickinson Eli Lilly Australia Allergan Biogen Essilor Australia Alphapharm bioMerieux Australia Evolution Health Amgen Blackmores FarmaForce Arjo Australia Boehringer Ingelheim Ferring Pharmaceuticals Aspen Australia Boston Scientific Int’l BV Fresenius Kabi Australia Astellas Pharma Australia Bristol Myers Squibb Australia Fresenius Medical Care Australia Astrazeneca Cardinal Health Galderma Australia Australian Nuclear Science and Technology Cepheid GE Australia Healthcare Organisation (ANSTO) Cochlear Getinge Australian Pharmaceutical Industries Coloplast Australia Gilead Sciences B Braun Australia CooperVision Australia GlaxoSmithKline Australia B Braun Avitum Australia Device Technologies Aust Grifols Australia Baxter Healthcare Ecolab Hach Bayer Edwards Lifesciences Henry Schein Halas © March 2020 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.1 Participant list Herbalife Australasia Mayne Pharma Group PerkinElmer Illumina Australia Medtronic Australasia Permobil Australia Implant Direct Merck Australia Pfizer Australia iNova Pharmaceuticals (Australia) Merck Serono Philips Electronics Australia Integrated DNA Technologies (IDT) Merck Sharp & Dohme Australia
[Show full text]
2017 Annual Report Our Opportunities Are Limited “Only by Our Mind’S Ability to Seek Creative Solutions to Some of the World’S Greatest Challenges.”
2017 ANNUAL REPORT OUR OPPORTUNITIES ARE LIMITED “ONLY BY OUR MIND’S ABILITY TO SEEK CREATIVE SOLUTIONS TO SOME OF THE WORLD’S GREATEST CHALLENGES.” THOMAS P. JOYCE, JR. Financial Operating Highlights (dollars in millions except per share data and number of associates) 2017 2016 Sales $ 18,329.7 $ 16,882.4 Operating Profit $ 3,021.2 $ 2,750.9 Net Earnings $ 2,469.8 $ 2,153.4 Net Earnings Per Share (diluted) $ 3.50 $ 3.08 Operating Cash Flow $ 3,477.8 $ 3,087.5 Capital Expenditures $ 619.6 $ 589.6 Capital Disposals $ 32.6 $ 9.8 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 2,890.8 $ 2,507.7 Number of Associates 67,000 62,000 Total Assets $ 46,648.6 $ 45,295.3 Total Debt * $ 10,522.1 $ 12,269.0 Stockholders’ Equity $ 26,367.8 $ 23,076.8 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 36,889.9 $ 35,345.8 * Long-Term Debt ($10,327.4 for 2017 and $9,674.2 for 2016) plus Notes Payable and Current Portion of Long-Term Debt ($194.7 for 2017 and $2,594.8 for 2016) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. ANNUAL REPORT 2017 DANAHER Life Sciences Every day, scientists around the world work at a molecular level to understand chronic disease and infections, develop new therapies and test new drugs. Our Life Sciences businesses make this leading-edge scientific research possible. Our capabilities extend far beyond research to power the creation of biopharmaceuticals, cell therapies and more.
[Show full text]
Participant List
PARTICIPANT LIST Please find below a list of current participants in the Quarterly Salary Review. For a complete list by super sector, sector and segment refer to Mercer WIN®. 3M Australia APL Logistics Australia 7-Eleven Stores Apotex A Menarini Australia APT Management Services (APA Group) A. Noble & Son Aquila Resources A.P.Moller-Maersk AS (AU) Arafura Resources Abbott Australasia Arch International AbbVie Arch Wood Protection (Aust) ACCIONA AU Asahi Beverages Australia ACCIONA Energy Oceania Ascom Australia ACCIONA Infrastructure Australia Aspen Australia Acer Computer Australia Astellas Pharma Australia Adama Australia Astrazeneca adidas Australia AT & T Global Network Services Australia AECOM ATCO Australia Alcon Atlas Iron Alexion Australasia Ausgrid (formerly EnergyAustralia) Alinta Energy Australian Catholic University Allergan Australian Computer Society Allnex Australia Australian Industry Group Allnex Resins Australia Australian Pharmaceutical Industries Alphapharm Australian Red Cross Blood Service Alstom Austrlian Timken Altura Mining Avant Insurance Amazon AVJennings Holdings American Express Global Business Travel Avon Products Australia Axalta Coating Systems (Australia) Amgen Bacardi-Martini Australia Ampacet Australia Barminco Amway of Australia BASF Australia Apex Tool Group Baxter Healthcare API Management Bayer © June 2018 Mercer Consulting (Australia) Pty Ltd Quarterly Salary Review 4.1 PARTICIPANT LIST Beam Global Australia Bristow Helicopters Australia Beckman Coulter - Diagnostics British American Tobacco Australia
[Show full text]
2014 Danaher Entered Into a Definitive Agreement with Netscout to Combine Danaher’S Communications Business with Netscout
DANAHER 2014 ANNUAL REPORT Danaher Financial Operating Highlights (dollars in millions except per share data and number of associates) 2014 2013 Sales $ 19,914 $ 19,118 Operating Profit $ 3,431 $ 3,275 Net Earnings $ 2,598 $ 2,695 Net Earnings Per Share (diluted) $ 3.63 $ 3.80 Operating Cash Flow $ 3,758 $ 3,585 Capital Expenditures $ 597 $ 552 Free Cash Flow (Operating Cash Flow less Capital Expenditures) $ 3,161 $ 3,033 Number of Associates 71,000 66,000 Total Assets $ 36,992 $ 34,672 Total Debt* $ 3,473 $ 3,499 Stockholders’ Equity $ 23,450 $ 22,451 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 26,923 $ 25,950 * Long-Term Debt ($3,401 for 2014 and $3,437 for 2013) plus Notes Payable and Current Portion of Long-Term Debt ($72 for 2014 and $62 for 2013) ENVIRONMENTAL TEST & MEASUREMENT INDUSTRIAL TECHNOLOGIES LIFE SCIENCES & DIAGNOSTICS DENTAL ENVIRONMENTAL Our products help protect the global water supply, ensure environmental stewardship, enhance the safety of personal data and improve business efficiencies. OurWater Quality platform provides instrumentation and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, waste, ground and ocean water in residential, commercial, industrial and natural resource applications. Our Gilbarco Veeder-Root platform is a leading worldwide provider of solutions and services focused on fuel dispensing, remote fuel management, point-of-sale and payment systems, environmental compliance, vehicle tracking and fleet management. REDUCING MAINTENANCE REQUIREMENTS AND COSTS WHILE INCORPORATING THE MOST EFFICIENT TECHNOLOGIES AVAILABLE, THE TROJANUVTORRENT™ LEADS THE WAY FOR LARGE-SCALE DRINKING WATER DISINFECTION. Thanks to leading-edge technology from TrojanUV, New York City’s water is safe to drink, right from the tap.
[Show full text]
Goldman Sachs & Co. LLC J.P. Morgan
DANAHER CORPORATION Offer to Exchange Up to 127,868,000 Shares of Common Stock of ENVISTA HOLDINGS CORPORATION Which are Owned by Danaher Corporation for Outstanding Shares of Common Stock of DANAHER CORPORATION THE EXCHANGE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON DECEMBER 13, 2019, UNLESS THE EXCHANGE OFFER IS EXTENDED OR TERMINATED. Danaher Corporation, a Delaware corporation (“Danaher”), is offering to exchange (the “Exchange Offer”) up to an aggregate of 127,868,000 shares of common stock, par value $0.01 per share (“Envista Common Stock”), of Envista Holdings Corporation, a Delaware corporation (“Envista”), for outstanding shares of common stock of Danaher (“Danaher Common Stock”) that are validly tendered and not validly withdrawn. This Exchange Offer is designed to permit you to exchange your shares of Danaher Common Stock for shares of Envista Common Stock at a 7% discount to the per-share value of Envista Common Stock, calculated as set forth in this prospectus subject to the upper limit described below. For each $100 of Danaher Common Stock accepted in this Exchange Offer, you will receive approximately $107.53 of Envista Common Stock, subject to an upper limit of 5.5784 shares of Envista Common Stock per share of Danaher Common Stock. This Exchange Offer does not provide for a lower limit or minimum exchange ratio. See “The Exchange Offer—Terms of the Exchange Offer.” IF THE UPPER LIMIT IS IN EFFECT AT THE TIME OF THE DETERMINATION OF THE FINAL EXCHANGE RATIO, THE FINAL EXCHANGE RATIO WILL BE FIXED AT THE UPPER LIMIT, AND UNLESS YOU PROPERLY WITHDRAW YOUR SHARES, YOU MAY RECEIVE LESS THAN $107.53 OF ENVISTA COMMON STOCK FOR EACH $100 OF DANAHER COMMON STOCK THAT YOU TENDER, AND YOU COULD RECEIVE MUCH LESS.
[Show full text]
2016 ANNUAL REPORT “I See Our Future As a Bright One
2016 ANNUAL REPORT “ I see our future as a bright one. We have a terrific team of hard-working, dedicated associates around the world. We have exciting new products coming out, providing customers with new and innovative solutions to their daily work.” THOMAS P. JOYCE, JR. President and Chief Executive Officer FINANCIAL OPERATING HIGHLIGHTS (dollars in millions except per share data and number of associates) 2016 2015 Sales $ 16,882.4 $ 14,433.7 Operating Profit $ 2,750.9 $ 2,162.2 Net Earnings $ 2,153.4 $ 1,746.7 Net Earnings Per Share (diluted) $ 3.08 $ 2.47 Operating Cash Flow $ 3,087.5 $ 2,832.2 Capital Expenditures $ 589.6 $ 512.9 Free Cash Flow (Operating Cash Flow less Capital Expenditures) $ 2,497.9 $ 2,319.3 Number of Associates 62,000 59,000 Total Assets* $ 45,295.3 $ 48,222.2 Total Debt ** $ 12,269.0 $ 12,870.4 Stockholders’ Equity $ 23,076.8 $ 23,764.0 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 35,345.8 $ 36,634.4 * Related to both continuing and discontinued operations ** Long-Term Debt ($9,674.2 for 2016 and $12,025.2 for 2015) plus Notes Payable and Current Portion of Long-Term Debt ($2,594.8 for 2016 and $845.2 for 2015) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. Life Sciences Every day, scientists around the world are working to understand the causes of and treatments for chronic diseases and infections at the cellular level. Our Life Sciences businesses make this leading-edge scientific research possible, and our capabilities extend beyond research to power the creation of biopharmaceuticals, cell therapies and more.
[Show full text]
5 Customers in the Diagnostics Industry Select Products Based on A
Customers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product’s ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under “—Competition.” The diagnostics business generally markets its products under the APERIO, BECKMAN COULTER, CEPHEID, HEMOCUE, IRIS, LEICA BIOSYSTEMS, MAMMATOME, RADIOMETER and SURGIPATH brands. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors. DENTAL The Company’s Dental segment provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a leading worldwide provider of a broad range of dental consumables, equipment and services, and is dedicated to driving technological innovations that help dental professionals improve clinical outcomes and enhance productivity. Sales in 2017 for this segment by geographic destination were: North America, 49%; Europe, 30%; Asia/Australia, 15% and all other regions, 6%. Danaher entered the dental business in 2004 through the acquisitions of KaVo and Gendex and has enhanced its geographic coverage and product and service breadth through subsequent acquisitions, including the acquisition of Sybron Dental Specialties in 2006, PaloDEx Group Oy in 2009 and Nobel Biocare Holding AG (“Nobel Biocare”) in 2014.
[Show full text]
Danaher Corporation 2016 Annual Report
2016 ANNUAL REPORT “ I see our future as a bright one. We have a terrific team of hard-working, dedicated associates around the world. We have exciting new products coming out, providing customers with new and innovative solutions to their daily work.” THOMAS P. JOYCE, JR. President and Chief Executive Officer FINANCIAL OPERATING HIGHLIGHTS (dollars in millions except per share data and number of associates) 2016 2015 Sales $ 16,882.4 $ 14,433.7 Operating Profit $ 2,750.9 $ 2,162.2 Net Earnings $ 2,153.4 $ 1,746.7 Net Earnings Per Share (diluted) $ 3.08 $ 2.47 Operating Cash Flow $ 3,087.5 $ 2,832.2 Capital Expenditures $ 589.6 $ 512.9 Free Cash Flow (Operating Cash Flow less Capital Expenditures) $ 2,497.9 $ 2,319.3 Number of Associates 62,000 59,000 Total Assets* $ 45,295.3 $ 48,222.2 Total Debt ** $ 12,269.0 $ 12,870.4 Stockholders’ Equity $ 23,076.8 $ 23,764.0 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 35,345.8 $ 36,634.4 * Related to both continuing and discontinued operations ** Long-Term Debt ($9,674.2 for 2016 and $12,025.2 for 2015) plus Notes Payable and Current Portion of Long-Term Debt ($2,494.8 for 2016 and $845.2 for 2015) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. Life Sciences Every day, scientists around the world are working to understand the causes of and treatments for chronic diseases and infections at the cellular level. Our Life Sciences businesses make this leading-edge scientific research possible, and our capabilities extend beyond research to power the creation of biopharmaceuticals, cell therapies and more.
[Show full text]
Danaher Corporation Annual Report 2018
Danaher Corporation Annual Report 2018 Form 10-K (NYSE:DHR) Published: February 21st, 2018 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-8089 ____________________________________ DANAHER CORPORATION (Exact name of registrant as specified in its charter) Delaware 59-1995548 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification Number) 2200 Pennsylvania Ave. N.W., Suite 800W Washington, D.C. 20037-1701 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: 202-828-0850 Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange On Which Registered Common Stock $.01 par value New York Stock Exchange €600,000,000 1.000% Senior Notes due 2019 New York Stock Exchange €250,000,000 Floating Rate Senior Notes due 2022 New York Stock Exchange €800,000,000 1.700% Senior Notes due 2022 New York Stock Exchange €800,000,000 2.500% Senior Notes due 2025 New York Stock Exchange €600,000,000 1.200% Senior Notes due 2027 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: NONE (Title of Class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
[Show full text]